EFFICACY OF ALPHA-INTERFERON MONOTHERAPY AND COMBINATION OF ALPHA-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
M. Persico
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C

Teuber, Gerlinde
Berg, Thomas
Hoffmann, Robert M.
Leifeld, Ludger
Lafrenz, Michael
Spengler, Ulrich
Pape, Gerd R.
Hopf, Uwe
Zeuzem, Stefan

January 2000

Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more effica...

Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C

G. Fattovich
I. Zagni
G. Fornaciari
E. Minola
P. Fabris
S. Boccia
M. Giusti
G. Abbati
M. Felder
P. Rovere
A. Redaelli
A. Tonon
R. Montanari
C. Paternoster
M. Distasi
E. Castagnetti
G. Tositti
C. Rizzo
S. Suppressa
M. Pantalena
L. Lomonaco
C. Scattolini
A. Tagger

March 2003

summary. Retreatment of relapser patients with chronic hepatitis C with the standard dose of interfe...

Alpha interferon and ribavirin combination therapy of chronic hepatitis D

Besisik, F
Kaymakoglu, S
Demir, K
Poturoglu, S
Danalioglu, A
Bozaci, M
Cakaloglu, Y
Karaca, C
Okten, A
Badur, S

January 2005

The success of alpha interferon (IFN-alpha) monotherapy for the treatment of chronic hepatitis D is ...

Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.

Collier, J
Chapman, R

January 2001

Combination therapy with ribavirin and interferon (IFN)-alpha for 6 to 12 months is currently the tr...

Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial

Van Vlierberghe, H.
Leroux-Roels, G
Adler, M.
Bourgeois, N.
Nevens, Frederik
Horsmans, Yves
Brouwer, J
Colle, I.
Delwaide, J.
Brenard, Réginald
Bastens, B.
Henrion, J.
de Vries, RA
de Galocsy, C
Michielsen, P.
Robaeys, G.
Bruckers, L.

January 2003

The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy wit...

Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial

Van Vlierberghe, H.
Leroux-Roels, G.
Adler, M.
Bourgeois, N.
Nevens, F.
Horsmans, Y.
Brouwer, J.
Colle, I.
Delwaide, Jean
Brenard, R.
Bastens, B.
Henrion, J.
de Vries, R. A.
de Galocsy, C.
Michielsen, P.
Robaeys, G.
Bruckers, L.

January 2003

The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy wit...

Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial

Van Vlierberghe, H.
Leroux-Roels, G.
Adler, M.
Bourgeois, N.
Nevens, F.
Horsmans, Y.
Brouwer, J.
Colle, I.
Delwaide, Jean
Brenard, R.
Bastens, B.
Henrion, J.
de Vries, R. A.
de Galocsy, C.
Michielsen, P.
Robaeys, G.
Bruckers, L.

January 2003

peer reviewedThe standard treatment for patients with chronic hepatitis C is a 6-12-month combinatio...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

Combination of interferon alfa-2b and ribavirin in relapsed or nonresponding chronic hepatitis C patients following interferon therapy

Laurentius A. Lesmana
Unggul Budihusodo
Nurul Akbar
Ali Sulaiman
Sjaifoellah Noer
Inge A. Kristanti
Rianto Setiabudy

November 2001

Twenty six patients (pts) with chronic hepatitis C (CHC) who reLapsed or non-responded following.int...

A Comparison of Interferon-Alpha-2b Induction Therapy with Interferon-Alpha-2b Plus Ribavirin Combination Therapy for the Treatment of Chronic Hepatitis C

Bilgehan AYGEN
Orhan YILDIZ
Fatih BOSTANCI
Ömer ÖZBAKIR
Selma GÖKAHMETOĞLU
Tahir E. PATIROĞLU

September 2004

The standard treatment for patients with chronic hepatitis C (CHC) is a 6-12-month combination thera...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

THE EFFECT OF INTERFERON ALFA AND RIBAVIRIN COMBINATION THERAPY IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C

Chemello, Liliana
Cavalletto, L
Bernardinello, E
Guido, Maria
Pontisso, Patrizia
Alberti, A.

January 1995

BACKGROUND: Chronic hepatitis C may lead to cirrhosis and hepatocellular carcinoma in a subset of pa...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
M. Persico
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C

Teuber, Gerlinde
Berg, Thomas
Hoffmann, Robert M.
Leifeld, Ludger
Lafrenz, Michael
Spengler, Ulrich
Pape, Gerd R.
Hopf, Uwe
Zeuzem, Stefan

January 2000

Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more effica...

Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C

G. Fattovich
I. Zagni
G. Fornaciari
E. Minola
P. Fabris
S. Boccia
M. Giusti
G. Abbati
M. Felder
P. Rovere
A. Redaelli
A. Tonon
R. Montanari
C. Paternoster
M. Distasi
E. Castagnetti
G. Tositti
C. Rizzo
S. Suppressa
M. Pantalena
L. Lomonaco
C. Scattolini
A. Tagger

March 2003

summary. Retreatment of relapser patients with chronic hepatitis C with the standard dose of interfe...

Alpha interferon and ribavirin combination therapy of chronic hepatitis D

Besisik, F
Kaymakoglu, S
Demir, K
Poturoglu, S
Danalioglu, A
Bozaci, M
Cakaloglu, Y
Karaca, C
Okten, A
Badur, S

January 2005

The success of alpha interferon (IFN-alpha) monotherapy for the treatment of chronic hepatitis D is ...

Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.

Collier, J
Chapman, R

January 2001

Combination therapy with ribavirin and interferon (IFN)-alpha for 6 to 12 months is currently the tr...

Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial

Van Vlierberghe, H.
Leroux-Roels, G
Adler, M.
Bourgeois, N.
Nevens, Frederik
Horsmans, Yves
Brouwer, J
Colle, I.
Delwaide, J.
Brenard, Réginald
Bastens, B.
Henrion, J.
de Vries, RA
de Galocsy, C
Michielsen, P.
Robaeys, G.
Bruckers, L.

January 2003

The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy wit...

Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial

Van Vlierberghe, H.
Leroux-Roels, G.
Adler, M.
Bourgeois, N.
Nevens, F.
Horsmans, Y.
Brouwer, J.
Colle, I.
Delwaide, Jean
Brenard, R.
Bastens, B.
Henrion, J.
de Vries, R. A.
de Galocsy, C.
Michielsen, P.
Robaeys, G.
Bruckers, L.

January 2003

The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy wit...

Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial

Van Vlierberghe, H.
Leroux-Roels, G.
Adler, M.
Bourgeois, N.
Nevens, F.
Horsmans, Y.
Brouwer, J.
Colle, I.
Delwaide, Jean
Brenard, R.
Bastens, B.
Henrion, J.
de Vries, R. A.
de Galocsy, C.
Michielsen, P.
Robaeys, G.
Bruckers, L.

January 2003

peer reviewedThe standard treatment for patients with chronic hepatitis C is a 6-12-month combinatio...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

Combination of interferon alfa-2b and ribavirin in relapsed or nonresponding chronic hepatitis C patients following interferon therapy

Laurentius A. Lesmana
Unggul Budihusodo
Nurul Akbar
Ali Sulaiman
Sjaifoellah Noer
Inge A. Kristanti
Rianto Setiabudy

November 2001

Twenty six patients (pts) with chronic hepatitis C (CHC) who reLapsed or non-responded following.int...

A Comparison of Interferon-Alpha-2b Induction Therapy with Interferon-Alpha-2b Plus Ribavirin Combination Therapy for the Treatment of Chronic Hepatitis C

Bilgehan AYGEN
Orhan YILDIZ
Fatih BOSTANCI
Ömer ÖZBAKIR
Selma GÖKAHMETOĞLU
Tahir E. PATIROĞLU

September 2004

The standard treatment for patients with chronic hepatitis C (CHC) is a 6-12-month combination thera...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

THE EFFECT OF INTERFERON ALFA AND RIBAVIRIN COMBINATION THERAPY IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C

Chemello, Liliana
Cavalletto, L
Bernardinello, E
Guido, Maria
Pontisso, Patrizia
Alberti, A.

January 1995

BACKGROUND: Chronic hepatitis C may lead to cirrhosis and hepatocellular carcinoma in a subset of pa...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
M. Persico
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

A. Mangia
G. L. Ricci
N. Minerva
V. Carretta
D. Bacca
M. Cela
M. Piattelli
M. Annese
G. Maio
D. Conte
V. Guadagnino
V. Pazienza
D. Festi
F. Spirito
A. Andriulli
PERSICO, Marcello

January 2005

We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginte...

EFFICACY OF ALPHA-INTERFERON MONOTHERAPY AND COMBINATION OF ALPHA-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS

Abstract

Extracted data

EFFICACY OF ALPHA-INTERFERON MONOTHERAPY AND COMBINATION OF ALPHA-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS

Abstract

Extracted data

Related items

Related items